Synexus Celebrates 21st Birthday With a Forward Order Book of Over $100 Million

MANCHESTER, England, April 9, 2013 /PRNewswire/ --

Since its launch 21 years ago Synexus has grown from a small clinic adjoining founder Dr Smith's surgery to the largest multinational organisation dedicated to the recruitment of patients and running of clinical trials at its 25 clinics across Europe and Africa.

Dr Christophe Berthoux, CEO of Synexus said: "We had an excellent 2012 and expect 2013 to be better. Our forward order book, which at this time exceeds $100 million, continues to grow. In the last two years we have undergone dramatic and positive change. To meet the growth in demand we have strengthened our management team and focussed on the therapy areas where we can add most value - cardiovascular, metabolic (diabetes and obesity), bone, respiratory and CNS (dementia and pain)."

The reorganisation includes a new global management team, reporting to the executive management board, which is responsible for HR, IT and patient recruitment. This has resulted in great improvement in patient recruitment with over 95% of trials achieving or exceeding their targets.

Synexus has also put in place a regional structure with managing directors being responsible for their regions including the day-to-day running of their sites, performance and profitability.

All regions report to COO Jane Restorick who has an overriding responsibility for data quality, patient care and the adherence of best clinical practice in every Synexus clinic.

Christophe explains the success of the Synexus model "We've seen our model being adopted far more widely as our clients in pharma and CROs get to grips with the urgent need to bring drugs to market more quickly and less expensively."

Synexus has shown that using its own Centres speeds up clinical trials, makes them more cost-effective and delivers thousands of patients. It has revolutionized the way late-stage clinical trials are carried out.  Traditionally, individual doctors recruited four patients or less on an opportunistic basis which, with studies involving thousands of patients, is enormously expensive and wholly impractical.

Christophe sums up "Our excellent progress is directly related to putting in place a professional structure which delivers quality data and patients. It has been a team effort which has been actively supported by our major shareholder Lyceum Capital. We are looking forward to a sustained period of growth."

INFORMATION:  
Simon Vane Percy
+44-(0)1737-821-890 / +44(0)7710-005910
[email protected]

SOURCE Synexus